Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3341323 | 0.85 | NPC1 (0.42) | GAANPC1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL3343024 | 0.74 | LIG1 (0.44) | GAANPC1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL2476221 | 0.74 | GAA (0.62) | GAASMN1; SMN2ALDH1A1POLBKMT2A | |
| SCHEMBL3340478 | 0.74 | TYK2 (0.51) | GAANPC1ALDH1A1POLBMAPT | |
| SCHEMBL19378588 | 0.74 | LMNA (0.53) | GAANPC1ALDH1A1KMT2AMEN1 | |
| SCHEMBL17063811 | 0.74 | JAK2 (0.52) | GAANPC1SMN1; SMN2ALDH1A1KMT2A | |
| Chloroneb SCHEMBL22739 | 0.73 | GAA (0.64) | GAANPC1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL13184244 | 0.72 | KDM4E (0.39) | GAANPC1SMN1; SMN2ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL28439646 | 0.72 | JAK2 (0.51) | GAANPC1SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL2775341 | 0.72 | LMNA (0.51) | GAANPC1SMN1; SMN2POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | GAA 4315/4885NPC1 241/4885SMN1; SMN2 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.